



Universiteit
Leiden
The Netherlands

HNPCC, molecular and clinical dilemmas

Wagner, A.

Citation

Wagner, A. (2005, April 27). *HNPCC, molecular and clinical dilemmas*. Macula, Boskoop.
Retrieved from <https://hdl.handle.net/1887/2719>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/2719>

Note: To cite this publication please use the final published version (if applicable).

List of tables and figures

Tables.

Table 1.	Proven and "candidate" HNPCC genes.	14
Table 2.	The Amsterdam criteria for the clinical diagnosis of HNPCC Families.	14
Table 3.	The Bethesda guidelines to select for MSI testing of colorectal tumours.	16
Table 4.	Selected markers for MSI analysis in colorectal cancer and criteria for the interpretation of MSI.	16
Table 5.	Cumulative lifetime risks of colorectal, endometrial, stomach, ovarian, urothelial, small bowel, biliary tract cancer and brain tumours in <i>MLH1</i> , <i>MSH2</i> and <i>MSH6</i> mutation carriers compared to the population risks.	33
Table 6.	Mean age of onset of colorectal, endometrial, stomach, ovarian, urothelial, small bowel, biliary tract cancer and brain tumours in <i>MLH1</i> , <i>MSH2</i> and <i>MSH6</i> mutation carriers.	33
Table 7.	Screening advises in HNPCC(-like) families.	38
Table 8.	Comparison of MSI and IHC analysis in 154 tumours of 119 families analysed for <i>MLH1</i> , <i>MSH2</i> and sometimes <i>MSH6</i> mutations.	51
Table 9.	Logistic regression model for selection for <i>MSH2</i> , <i>MLH1</i> mutation analysis.	51

Figures.

Figure 1.	A.S. Warthin (1866-1931), H.T. Lynch.	13
Figure 2.	The crystal structure of the MutS dimer.	17
Figure 3.	Schematic representation of the eukaryotic mismatch repair (MMR) pathways.	22
Figure 4.	Schematic representation of the Knudson model.	24
Figure 5.	The adenoma-carcinoma sequence.	26
Figure 6.	A schematic representation of the Wnt-signalling pathway.	27
Figure 7.	A schematic representation of the KRAS-signalling pathway.	28
Figure 8.	A schematic representation of the TGF β -signalling pathway.	29
Figure 9.	A schematic representation of the p53-pathway.	30
Figure 10.	A practical flowchart for the management of individuals with multiple or early onset HNPCC-associated tumours, and of families with clustering of HNPCC-associated tumours.	50

Tables and Figures	169
--------------------	-----

Curriculum Vitae

Anja Wagner werd op 13 december 1968 te Rotterdam geboren.

1973-1975	Kleuterschool "Oud Charlois" te Rotterdam.
1975-1981	Derde Rotterdamse Schoolvereniging.
1981-1987	Gymnasium Erasmianum te Rotterdam.
1987-1995	Studie Geneeskunde, Erasmus Universiteit Rotterdam.
1992/3	Afstudeeronderzoek "De behandeling en prognose van onstabiele angina pectoris op de ICCU van een Indonesisch ziekenhuis", Ujung Pandang, Sulawesi.
1995-1999	AGNIO afdeling Klinische Genetica, Erasmus Medisch Centrum Rotterdam, in het bijzonder bij genetisch onderzoek en advies bij erfelijke tumoren onder leiding van Prof. Dr. M.F. Niermeijer en Dr. E.J. Meijers-Heijboer.
1999-2004	AGIKO afdeling Klinische Genetica, Erasmus Medisch Centrum Rotterdam; opleiding onder leiding van Prof. Dr. M.F. Niermeijer en Dr. E.J. Meijers-Heijboer, promotie onderzoek onder leiding van Prof. Dr. R. Fodde, afdeling Humane en Klinische Genetica, Leids Universitair Medisch Centrum.
2004-heden	Klinisch Geneticus afdeling Klinische Genetica, Erasmus Medisch Centrum Rotterdam, verantwoordelijk voor de patiëntenzorg op de Polikliniek Erfelijke Maag-, Darm-, Leverziekten, de polikliniek Erfelijke Kinderoncologie en contactpersoon met betrekking tot genodermatosen.

Tijdens haar studie geneeskunde was Anja één van de oprichters van de "Werkgroep Andere Geneeswijzen", welke tot doel had studenten over andere geneeswijzen dan de reguliere te informeren. In 2000 was zij enkele weken te gast bij Prof. Dr. H.T. Lynch op de afdeling Public Health and Preventive Medicine, Creighton University, Omaha, USA. Zij woonde daar enkele informatieve familie-bijeenkomsten bij. Tenslotte was zij als deskundige betrokken bij het opzetten van de "Werkgroep Erfelijkheid" van de Borstkanker Vereniging Nederland (BVN).

List of publications

- Wagner A, et al. Preliminary experience with predictive testing for insulin-dependent diabetes mellitus. *Lancet* 1995;346:380-381
- Verhoog LC, Brekelmans C, Seynaeve C, Bosch L van den, Dahmen G, Geel AN van, Tilanus M, Bartels C, Wagner A, et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of *BRCA1*. *Lancet* 1998;35:316-21
- Verhoog LC, Brekelmans C, Seynaeve C, Dahmen G, Geel AN van, Bartels CC, Tilanus-Linthorst MM, Wagner A, et al. Survival in hereditary breast cancer associated with germline mutations of *BRCA2*. *JClinOncol* 1999;17:3396-3402
- Lodder LN, Frets PG, Trijsburg RW, Meijers-Heijboer EJ, Klijn JGM, Duivenvoorden HJ, Tibben A, Wagner A et al. Presymptomatic testing for *BRCA1* and *BRCA2*: how distressing are the pretest weeks? *JMedGenet* 1999;36:906-13
- Meijers-Heijboer EJ, Verhoog LC, Brekelmans CTM, Seynaeve C, Tilanus-Linthorst MMA, Wagner A et al. Presymptomatic DNA testing and prophylactic surgery in families with a *BRCA1* or *BRCA2* mutation. *Lancet* 2000 :355;2015
- Wagner A, et al. Atypical HNPCC owing to *MSH6* germline mutations; study of a large Dutch pedigree. *J Med Genet* 2001;38:318-22
- Stella A, Wagner A, et al. A nonsense mutation in *MLH1* causes exon skipping in three unrelated HNPCC families. *Cancer Research* 2001;61:7020-4
- Verhoog LC, van den Ouweland AMW, Berns E, van Veghel-Plandsoen MM, van Staveren IL, Wagner A, et al. Large regional differences in frequency of distinct *BRCA1/BRCA2* mutations in 157 Dutch breast and/or ovarian cancer families. *EurJCancer* 2001;37:2082-2090
- Lodder LN, Frets PG, Trijsburg RW, Meijers-Heijboer EJ, Klijn JGM, Duivenvoorden HJ, Tibben A, Wagner A, et al. Psychological impact of receiving a *BRCA1/BRCA2* test result. *AmJMed Genet* 2001;98 :15-24
- Lodder LN, Frets PG, Trijsburg RW, Tibben A, Meijers-Heijboer EJ, Duivenvoorden HJ, Wager A, et al. Men at risk of being a mutation carrier for hereditary breast/ovarian cancer: an exploration of attitudes and psychological functioning during genetic testing. *EurJHumGenet* 2001;9 :492-500
- Wagner A, et al. A 10Mb paracentric inversion of chromosome 2p inactivates *MSH2* and is responsible for HNPCC in a North-American kindred. *Genes, Chromosomes and Cancer* 2002;35:49-57
- Wagner A, et al. Genetic testing in Hereditary nonpolyposis colorectal cancer families with a *MSH2*, *MLH1* or *MSH6* mutation. *JMG* 2002;39:833-7
- Wagner A, et al. Molecular Analysis of Hereditary Nonpolyposis Colorectal Cancer in the United States: High Mutation Detection Rate among Clinically Selected Families and Characterization of an American Founder Genomic Deletion of the *MSH2* gene. *Am J Hum Genet* 2003;72:1088-1100
- Meijers-Heijboer H, Wijnen J, Vasen H, Wasielewski M, Wagner A, et al. The check2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype. *Am Jhum Genet* 2003;72:1308-1314
- Lynch HT, Taylor RJ, Lynch J, Knezetic JA, Barrows A, Fodde R, Wijnen J, Wagner A, et al. Multiple primary cancer, including transitional cell carcinoma of the upper uroepithelial tract in a multigeneration HNPCC family: Molecular and management implications. *AmJGastroent* 2003;98:664-670
- Watson P, Narod SA, Fodde R, Wagner A, et al. Carrier risk status changes resulting from mutation testing in hereditary non-polyposis colorectal cancer and hereditary breast-ovarian cancer. *Jmed Genet* 2003;40:591-596
- Lynch HT, Coronel S, Okimoto R, Hampel H, Sweet K, Lynch JF, Barrows A, Wijnen J, Klift H van der, Franken P, Wagner A, et al. A Founder Mutation of the *MSH2* gene and Hereditary Nonpolyposis Colorectal Cancer in the United States. *JAMA* 2004;291:718-24
- Hendriks YMC, Wagner A, et al. Cancer Risk in Hereditary Non Polyposis Colorectal Cancer Associated with *MSH6* Mutations; Consequences for Counselling and Surveillance. *Gastroenterology* 2004;27:17-25
- Jong AE de, Puijenbroek M van, Hendriks Y, Tops C, Wijnen J, Ausems M, Meijers-Heijboer EJ, Wagner A et al. Microsatellite Instability, Immunohistochemistry, and Additional PMS2 staining in Suspected Hereditary Nonpolyposis Colorectal Cancer. *Clin Cancer Res* 2004;10:972-80
- Seynaeve C, Verhoog LC, van de Bosch LMC, van Geel AN, Menke-Pluijmers M, Meijers-Heijboer EJ, van den Ouweland amw, Wagner A, et al. Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy. *EurJCancer* 2004;40:1150-1158
- Klevering BJ, Mauger A, Wagenr A, et al. Three families displaying the combination of Stargardt's disease with cone-rod dystrophy or retinitis pigmentosa. *Ophthalmology* 2004;111:546-553

